论文部分内容阅读
利用基因工程重组技术获得了三种嵌合抗原，两种为丙型肝炎病毒（ＨＣＶ）结构区核壳蛋白Ｃ２２和ＮＳ３非结构区Ｃ３３ｃ双表位的嵌合抗原Ｂ１和Ｂ２，另一种是既具有上述两段优势抗原，还包括ＮＳ４非结构区Ｃ１００多表位的嵌合抗原Ｃ２５。在大肠杆菌水解酶阴性的Ｂ株菌中表达的产物，经ＳＤＳ一ＰＡＧＥ分析，Ｂ１、Ｂ２和Ｃ２５嵌合抗原分子量分别为４３、５３和７０ｋＤ，抗原蛋白表达量分别各占电泳蛋白条带的４０％、１０％和３５％左右。３个嵌合抗原的免疫活性分析证明，它们都具有相应区段的免疫活性。用嵌合抗原分别组装成ＥＩＡ试剂盒，经国家ＨＣＶ诊断试剂质控参比血清验证，Ｂ１嵌合抗原的抗体检出率为９５％Ｂ２嵌合抗原为９１％，Ｃ２５为９４％，均高于Ｃ３３ｃ和ＭＡＰＣＰ１９混合抗原（８８％）。Ｂ１嵌合抗原与核壳蛋白Ｃ区和非结构ＮＳ４区（Ｃ一ＮＳ４）双表位化学嵌合多肽抗原联合应用，抗体检出率高达９７％，完全符合国家ＨＣＶ诊断试剂质控要求。
Three chimeric antigens were obtained by genetic engineering recombination technology, two were chimeric antigens B1 and B2 of hepatitis C virus (HCV) structural domain nucleocapsid protein C22 and NS3 non-structural domain C33c double epitopes, and the other was Both have the above two advantages of antigens, but also includes NS4 non-structural C100 multi-epitope chimeric antigen C25. The results of SDS-PAGE showed that the molecular weights of B1, B2 and C25 chimeric antigens were 43, 53 and 70 kD, respectively, and the expression of antigenic proteins were respectively accounted for by electrophoretic bands 40%, 10% and 35%. Immunogenicity analysis of the three chimeric antigens demonstrated that they all have the immunosorbent activity of the corresponding segment. The chimeric antigens were respectively assembled into EIA kit. The quality control reference serum of the national HCV diagnostic reagent was used to verify that the detection rate of B1 chimeric antigen was 95%, the chimeric antigen was 91%, the C25 was 94% Antigen (88%) was mixed with C33c and MAPCP19. B1 chimeric antigen and the combination of nucleocapsid protein C region and NS4 (C-NS4) dual-epitope chimeric peptide antigen, antibody detection rate as high as 97%, in full compliance with the national HCV diagnostic reagent quality control requirements.